MD4608C1 - Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate - Google Patents

Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate

Info

Publication number
MD4608C1
MD4608C1 MDA20150031A MD20150031A MD4608C1 MD 4608 C1 MD4608 C1 MD 4608C1 MD A20150031 A MDA20150031 A MD A20150031A MD 20150031 A MD20150031 A MD 20150031A MD 4608 C1 MD4608 C1 MD 4608C1
Authority
MD
Moldova
Prior art keywords
methods
refolded
hyperbaric
producing
microorganisms
Prior art date
Application number
MDA20150031A
Other languages
English (en)
Russian (ru)
Other versions
MD20150031A2 (ro
MD4608B1 (ro
Inventor
Николас Пьер Ив КАРБУЛЕК
Жильда Мериан
Рене Лабатю
Лионель Жерант
Original Assignee
Merial Inc.
Top Industrie S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc., Top Industrie S.A.S. filed Critical Merial Inc.
Publication of MD20150031A2 publication Critical patent/MD20150031A2/ro
Publication of MD4608B1 publication Critical patent/MD4608B1/ro
Publication of MD4608C1 publication Critical patent/MD4608C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/015—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with pressure variation, shock, acceleration or shear stress or cavitation
    • A23L3/0155—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with pressure variation, shock, acceleration or shear stress or cavitation using sub- or super-atmospheric pressures, or pressure variations transmitted by a liquid or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01041—Sterol 24-C-methyltransferasee (2.1.1.41)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Invenţia se referă la dispozitive hiperbarice pentru inactivarea microorganismelor şi virusurilor, în acelaşi timp păstrând imunogenitatea lor şi pentru obţinerea şi producerea proteinelor solubile, dezagregate, repliate sau active imunogenice sau terapeutice din incluziuni produse de procariote sau eucariote. Invenţia include metode de inactivare hiperbarică a organismelor patogene şi metode de producere a compoziţiilor de vaccin utilizând agenţi patogeni inactivaţi. Microorganismele inactivate hiperbaric sunt mai sigure şi mai imunogenice decât microorganismele inactivate chimic. În mod similar, proteinele solubilizate au proprietăţi superioare comparativ cu proteinele intens agregate, inclusiv reacţii imune nespecifice reduse.
MDA20150031A 2012-08-30 2013-08-30 Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate MD4608C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261694968P 2012-08-30 2012-08-30
US201361830425P 2013-06-03 2013-06-03
PCT/US2013/057426 WO2014036345A2 (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Publications (3)

Publication Number Publication Date
MD20150031A2 MD20150031A2 (ro) 2015-10-31
MD4608B1 MD4608B1 (ro) 2018-12-31
MD4608C1 true MD4608C1 (ro) 2019-07-31

Family

ID=49162270

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150031A MD4608C1 (ro) 2012-08-30 2013-08-30 Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate

Country Status (18)

Country Link
US (3) US9315553B2 (ro)
EP (2) EP2890393A2 (ro)
JP (2) JP6405308B2 (ro)
KR (1) KR102208844B1 (ro)
CN (3) CN104717976A (ro)
AP (1) AP2015008331A0 (ro)
AU (4) AU2013308627B2 (ro)
BR (1) BR112015004463B8 (ro)
CA (2) CA2883296A1 (ro)
EA (1) EA031988B1 (ro)
ES (1) ES2744709T3 (ro)
HK (2) HK1211873A1 (ro)
MD (1) MD4608C1 (ro)
MX (3) MX358782B (ro)
NZ (3) NZ706288A (ro)
PH (1) PH12015500700A1 (ro)
RU (1) RU2647568C2 (ro)
WO (2) WO2014036349A1 (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
ZA201501696B (en) 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
NZ706288A (en) * 2012-08-30 2016-06-24 Merial Inc Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
US9909114B2 (en) 2013-03-28 2018-03-06 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CN104758944B (zh) 2015-04-02 2017-11-28 中国科学院过程工程研究所 一种疫苗制剂及其制备方法和用途
JP2018082987A (ja) * 2016-11-25 2018-05-31 株式会社日立製作所 ウイルス不活化方法及びウイルス不活化装置
JP2020152644A (ja) * 2019-03-18 2020-09-24 国立大学法人愛媛大学 Ｖｎａｒのリフォールディング方法およびｖｎａｒの製造方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112120012B (zh) * 2020-09-30 2022-03-22 广东康盾创新产业集团股份公司 一种car-t细胞冻存方法
BR102021000794A2 (pt) * 2021-01-15 2022-07-26 Fundação Oswaldo Cruz Proteína quimérica, kit, método para diagnóstico de leishmaniose, uso de uma proteína quimérica, composição vacinal contra leishmaniose visceral, e, uso de uma composição vacinal

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US6489450B2 (en) 1998-07-09 2002-12-03 University Technology Corporation High pressure refolding of protein aggregates and inclusion bodies
CA2374121A1 (en) 1999-05-28 2000-12-07 Universite Laval Inactivation of food spoilage and pathogenic microorganisms by dynamic high pressure
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
DK1221955T3 (da) 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
US7615617B2 (en) 1999-10-25 2009-11-10 University Of Delaware Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
AU2002246493A1 (en) 2000-08-10 2002-07-30 Boston Biomedica, Inc. Pressure cycling inactivation of pathogens in biological materials used for therapeutics or vaccines
US6635223B2 (en) * 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
MXPA03003867A (es) * 2000-10-31 2004-10-15 Univ Colorado Regents Desagregacion mejorada de proteina y replegamiento utilizando alta presion.
WO2004024027A2 (en) 2002-06-07 2004-03-25 University Of Florida Endodontic files made using bulk metallic glasses
SE525457C2 (sv) * 2002-06-24 2005-02-22 Flow Holdings Sagl Förfarande för åstadkommande av en tryckändring mellan två trycktillstånd, högtryckspressanordning samt användning av förfarande eller högtryckspressanordning
EP1687023B1 (en) * 2003-11-05 2012-10-03 C.B.F. Leti, S.L. Unipersonal Use of specific histones for the treatment of parasitic diseases
US7993580B2 (en) 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
CN101568427A (zh) 2005-11-21 2009-10-28 巴罗福德公司 用于蛋白质的高压重折叠的装置和方法
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
JP2010503683A (ja) 2006-09-15 2010-02-04 バロフォールド， インコーポレイテッド 免疫原性低下のためのタンパク質の高圧処理
WO2008124139A1 (en) 2007-04-05 2008-10-16 Barofold, Inc. High pressure inclusion body solubilization in the presence of a protease
WO2008124134A2 (en) 2007-04-05 2008-10-16 Barofold, Inc. High-pressure refolding of proteins in the presence of binding partners
EP2207890A4 (en) 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
JP5890096B2 (ja) * 2007-12-21 2016-03-22 ゾエティス・エルエルシー 熱処理バクテリンおよびそのような熱処理バクテリンから調製された乳剤ワクチン
BRPI0800357A2 (pt) 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz método para produção de uma vacina estabilizada
EP2899203B1 (en) 2008-05-08 2019-07-10 Boehringer Ingelheim Animal Health USA Inc. Leishmania vaccine using sand fly salivary immunogen
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
AR073170A1 (es) 2008-05-21 2010-10-20 Infectious Disease Res Inst Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis
WO2009155102A2 (en) 2008-05-30 2009-12-23 Barofold, Inc. Method for derivatization of proteins using hydrostatic pressure
US20110070219A1 (en) 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
US20120304872A1 (en) * 2010-02-01 2012-12-06 Avure Technologies Ab High-pressure arrangement with locking element preventing rotation of load basket
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备
US8697848B2 (en) 2010-07-19 2014-04-15 The Regents Of The University Of Colorado Method for reducing immunogenicity of therapeutic protein compositions
NZ706288A (en) 2012-08-30 2016-06-24 Merial Inc Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
ZA201501696B (en) * 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Also Published As

Publication number Publication date
CA2883303A1 (en) 2014-03-06
AP2015008331A0 (en) 2015-03-31
AU2017200301A1 (en) 2017-02-16
US9315553B2 (en) 2016-04-19
AU2017201724A1 (en) 2017-03-30
US9169302B2 (en) 2015-10-27
NZ705790A (en) 2016-06-24
WO2014036345A2 (en) 2014-03-06
CN104768577B (zh) 2020-06-09
PH12015500700B1 (en) 2015-05-25
JP2015528466A (ja) 2015-09-28
BR112015004463A2 (pt) 2017-08-08
NZ706288A (en) 2016-06-24
CN104717976A (zh) 2015-06-17
JP6438396B2 (ja) 2018-12-12
WO2014036345A3 (en) 2014-06-26
US20140065187A1 (en) 2014-03-06
NZ715459A (en) 2017-05-26
MX2015002701A (es) 2015-12-01
US20140072594A1 (en) 2014-03-13
RU2015111255A (ru) 2016-10-20
EP2890393A2 (en) 2015-07-08
EA031988B1 (ru) 2019-03-29
AU2017201724B2 (en) 2019-01-17
HK1211874A1 (en) 2016-06-03
CN108578679A (zh) 2018-09-28
US20170081372A1 (en) 2017-03-23
AU2013308627A1 (en) 2015-04-09
EP2890392A1 (en) 2015-07-08
EP2890392B1 (en) 2019-04-17
MX2015002699A (es) 2015-12-01
US10364274B2 (en) 2019-07-30
MD20150031A2 (ro) 2015-10-31
KR102208844B1 (ko) 2021-01-27
BR112015004463B1 (pt) 2021-08-24
EA201500275A1 (ru) 2015-07-30
ES2744709T3 (es) 2020-02-26
RU2647568C2 (ru) 2018-03-16
AU2013308623B2 (en) 2017-03-02
CN104768577A (zh) 2015-07-08
BR112015004463B8 (pt) 2022-06-28
MD4608B1 (ro) 2018-12-31
CA2883296A1 (en) 2014-03-06
AU2013308627B2 (en) 2016-10-27
AU2013308623A1 (en) 2015-04-02
MX2021004478A (es) 2021-06-04
PH12015500700A1 (en) 2015-05-25
MX358782B (es) 2018-09-04
KR20150063403A (ko) 2015-06-09
HK1211873A1 (en) 2016-06-03
WO2014036349A1 (en) 2014-03-06
JP2015529462A (ja) 2015-10-08
JP6405308B2 (ja) 2018-10-17

Similar Documents

Publication Publication Date Title
MD4608C1 (ro) Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
BR112014024159A2 (pt) Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
MX2017015881A (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
MX349119B (es) Vacuna de virus de dengue inactivado.
EA201290956A1 (ru) Вакцина против вич
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
PH12015501333A1 (en) Method of making a mycoplasma vaccine
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
EA033027B1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
MX2014014521A (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
MX2015014005A (es) Complejo inmunogenico para vacunacion y metodo de obtencion.
EA201390452A1 (ru) Вакцина
PL410063A1 (pl) Szczepionka, kompozycja farmaceutyczna, nośnik kwasów nukleinowych oraz innych substancji aktywnych biologicznie, zastosowanie kompozycji do wytwarzania szczepionki oraz zastosowanie kationowych pochodnych poliprenoli PTAI do wytwarzania substancji immunomodulujących

Legal Events

Date Code Title Description
FG4A Patent for invention issued